Topotecan
- Generic Name
- Topotecan
- Brand Names
- Hycamtin, Potactasol, Topotecan Hospira
- Drug Type
- Small Molecule
- Chemical Formula
- C23H23N3O5
- CAS Number
- 123948-87-8
- Unique Ingredient Identifier
- 7M7YKX2N15
- Background
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
- Indication
用于小细胞肺癌（SCLC）和一线治疗失败的晚期转移性卵巢癌。
- Associated Conditions
- Acute Myeloid Leukemia, Ewing's Sarcoma, Refractory Neuroblastoma, Metastatic Rhabdomyosarcoma, Recurrent Stage IVB Cervical Cancer, Refractory CNS lymphoma, Refractory CNS malignancy, Refractory, metastatic Ovarian cancer, Relapsed Platinum Sensitive Small Cell Lung Cancer (SCLC)
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
- Conditions
- Platinum-resistant Ovarian Cancer
- Interventions
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Genmab
- Target Recruit Count
- 530
- Registration Number
- NCT06619236
- Locations
- 🇺🇸
Center of Hope, Reno, Nevada, United States
🇺🇸Orlando Health Cancer Institute - Downtown Orlando, Orlando, Florida, United States
🇺🇸JamesCare Gynecologic Oncology at Mill Run, Hilliard, Ohio, United States
PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Biotheus Inc.
- Target Recruit Count
- 404
- Registration Number
- NCT06616532
- Locations
- 🇨🇳
Jilin Provincial Tumor Hospital, Changchun, China
🇨🇳Affiliated Hospital of Nantong University, Nantong, Jiangsu, China
🇨🇳The First Affiliated Hospital Of Ningbo University, Ningbo, Zhejiang, China
A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-09-25
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Target Recruit Count
- 438
- Registration Number
- NCT06612151
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Oral Topotecan With Toripalimab for Patients With Endometrial Cancer
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT06548763
- Locations
- 🇨🇳
Fudan university shanghai cancer center, Deparment of gynecologic oncology, Shanghai, Shanghai, China
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
- Conditions
- NeuroblastomaChildhood NeuroblastomaHigh-risk Neuroblastoma
- Interventions
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT06528496
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 714
- Registration Number
- NCT06500026
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer
- First Posted Date
- 2024-07-12
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Hansoh BioMedical R&D Company
- Target Recruit Count
- 460
- Registration Number
- NCT06498479
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
- Conditions
- Relapsed Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT06496048
- Locations
- 🇨🇳
Jilin Provincial Tumor Hospital, Jilin, China
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
- Conditions
- Cervical Cancer
- Interventions
- First Posted Date
- 2024-06-14
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 686
- Registration Number
- NCT06459180
- Locations
- 🇺🇸
USA Mitchell Cancer Institute-Clinical Trials ( Site 4126), Mobile, Alabama, United States
🇺🇸Providence Alaska Medical Center ( Site 4137), Anchorage, Alaska, United States
🇺🇸HonorHealth (HH) ( Site 8002), Phoenix, Arizona, United States
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
- Conditions
- Extensive-stage Small-cell Lung CancerSmall-cell Lung Cancer
- Interventions
- Drug: BNT327 Dose Level 1 (DL1)Drug: BNT327 Dose Level 2 (DL2)
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 110
- Registration Number
- NCT06449209
- Locations
- 🇦🇺
Peninsula Oncology Centre, Frankston, Australia
🇹🇷Hacettepe University Medical Faculty Oncology Hospital, Ankara, Turkey
🇹🇷Memorial Ankara Hospital, Ankara, Turkey
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.